Significant US Expansion LGM Pharma is actively expanding its manufacturing footprint in the United States with a recent investment of 15 million dollars across facilities in Texas and Colorado, including an additional 5 million dollar boost in Colorado Springs to produce niche oral solid dose products. This expansion presents opportunities for supply chain partnerships, formulation development collaborations, and regulatory support for companies seeking local manufacturing capabilities.

Focus on Advanced Delivery Technologies The company's specialization in innovative drug delivery systems such as injectables, transdermal, nasal, inhalation, ophthalmic, and sublingual therapies makes it an attractive partner for businesses developing complex drug formulations requiring specialized manufacturing and regulatory expertise.

Robust API Supply Chain LGM Pharma’s extensive network of approved API suppliers, including sources approved by major regulators like FDA, EDQM, and PMDA, provides a reliable supply chain solution for pharmaceutical companies looking to secure high-quality active ingredients for new drug developments or generic products.

Strong Industry Experience With over 18 years in the pharmaceutical manufacturing sector and ISO 9001 certification, LGM Pharma offers proven expertise in supporting clients through drug development to commercialization, making it a dependable partner for companies seeking comprehensive development, regulatory, and manufacturing support.

Market-Ready API Leadership LGM Pharma’s focus on API sourcing and its expansion into newly approved APIs with full technical and regulatory documentation offer opportunities for negotiation in API supply agreements, particularly for companies sourcing high-value, market-ready molecules to accelerate their product launch timelines.